

Marcela F Pasetti

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7609550/publications.pdf>

Version: 2024-02-01

121
papers

5,534
citations

71061

41
h-index

88593

70
g-index

128
all docs

128
docs citations

128
times ranked

5567
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Measles susceptibility in maternal-infant dyads in Bamako, Mali. <i>Vaccine</i> , 2022, 40, 1316-1322. | 1.7 | 1 |
| 2 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of VIS649 (Sibeprenlimab), an APRIL-Neutralizing IgG2 Monoclonal Antibody, in Healthy Volunteers. <i>Kidney International Reports</i> , 2022, 7, 993-1003. | 0.4 | 18 |
| 3 | Altered Gut Microbiome and Fecal Immune Phenotype in Early Preterm Infants With Leaky Gut. <i>Frontiers in Immunology</i> , 2022, 13, 815046. | 2.2 | 10 |
| 4 | Functional and structural modifications of influenza antibodies during pregnancy. <i>IScience</i> , 2022, 25, 104088. | 1.9 | 7 |
| 5 | Efficient production of immunologically active <i>Shigella</i> invasion plasmid antigens IpaB and IpaH using a cell-free expression system. <i>Applied Microbiology and Biotechnology</i> , 2022, 106, 401-414. | 1.7 | 5 |
| 6 | Epithelial and Neutrophil Interactions and Coordinated Response to <i>Shigella</i> in a Human Intestinal Enteroid-Neutrophil Coculture Model. <i>MBio</i> , 2022, 13, . | 1.8 | 8 |
| 7 | Highly Specialized Carbohydrate Metabolism Capability in <i>Bifidobacterium</i> Strains Associated with Intestinal Barrier Maturation in Early Preterm Infants. <i>MBio</i> , 2022, 13, . | 1.8 | 10 |
| 8 | Respiratory Syncytial Virus (RSV) Neutralizing Antibodies at Birth Predict Protection from RSV Illness in Infants in the First 3 Months of Life. <i>Clinical Infectious Diseases</i> , 2021, 73, e4421-e4427. | 2.9 | 42 |
| 9 | Adjustments for oral fluid quality and collection methods improve prediction of circulating tetanus antitoxin: Approaches for correcting antibody concentrations detected in a non-invasive specimen. <i>Vaccine</i> , 2021, 39, 423-430. | 1.7 | 2 |
| 10 | Low dose recombinant full-length circumsporozoite protein-based <i>Plasmodium falciparum</i> vaccine is well-tolerated and highly immunogenic in phase 1 first-in-human clinical testing. <i>Vaccine</i> , 2021, 39, 1195-1200. | 1.7 | 18 |
| 11 | Tick extracellular vesicles enable arthropod feeding and promote distinct outcomes of bacterial infection. <i>Nature Communications</i> , 2021, 12, 3696. | 5.8 | 27 |
| 12 | Human Breast Milk Enhances Intestinal Mucosal Barrier Function and Innate Immunity in a Healthy Pediatric Human Enteroid Model. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 685171. | 1.8 | 16 |
| 13 | Safety and immunogenicity of Vi-typhoid conjugate vaccine co-administration with routine 9-month vaccination in Burkina Faso: A randomized controlled phase 2 trial. <i>International Journal of Infectious Diseases</i> , 2021, 108, 465-472. | 1.5 | 14 |
| 14 | Maternal and neonatal immunization in the Americas: The benefits, the hurdles, and the way forward. <i>Vaccine</i> , 2021, 39, B1-B2. | 1.7 | 0 |
| 15 | Immunogenicity and Efficacy of Live-Attenuated <i>Salmonella</i> Typhimurium Vaccine Candidate CVD 1926 in a Rhesus Macaque Model of Gastroenteritis. <i>Infection and Immunity</i> , 2021, 89, e0008721. | 1.0 | 5 |
| 16 | Linked vaccination coverage surveys plus serosurveys among Ethiopian toddlers undertaken three years apart to compare coverage and serologic evidence of protection in districts implementing the RED-QI approach. <i>Vaccine</i> , 2021, 39, 5802-5813. | 1.7 | 4 |
| 17 | Repertoire of Naturally Acquired Maternal Antibodies Transferred to Infants for Protection Against Shigellosis. <i>Frontiers in Immunology</i> , 2021, 12, 725129. | 2.2 | 15 |
| 18 | A Novel Recombinant Influenza Virus Neuraminidase Vaccine Candidate Stabilized by a Measles Virus Phosphoprotein Tetramerization Domain Provides Robust Protection from Virus Challenge in the Mouse Model. <i>MBio</i> , 2021, 12, e0224121. | 1.8 | 21 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | Functional antibodies as immunological endpoints to evaluate protective immunity against <i>Shigella</i> . Human Vaccines and Immunotherapeutics, 2020, 16, 197-205. | 1.4 | 21 |
| 20 | Oral Shigella Vaccines. , 2020, , 515-536. | | 7 |
| 21 | Overcoming Waning Immunity in Pertussis Vaccines: Workshop of the National Institute of Allergy and Infectious Diseases. Journal of Immunology, 2020, 205, 877-882. | 0.4 | 17 |
| 22 | Pre-existing Helicobacter pylori serum IgG enhances the vibriocidal antibody response to CVD 103-HgR live oral cholera vaccine in Malian adults. Scientific Reports, 2020, 10, 16871. | 1.6 | 4 |
| 23 | Evaluation of a standardised Vi poly-l-lysine ELISA for serology of Vi capsular polysaccharide antibodies. Biologicals, 2020, 66, 21-29. | 0.5 | 6 |
| 24 | The SENIEUR protocol and the efficacy of hepatitis B vaccination in healthy elderly persons by age, gender, and vaccine route. Immunity and Ageing, 2020, 17, 9. | 1.8 | 8 |
| 25 | Pregnancy level of estradiol attenuated virus-specific humoral immune response in H5N1-infected female mice despite inducing anti-inflammatory protection. Emerging Microbes and Infections, 2019, 8, 1146-1156. | 3.0 | 7 |
| 26 | Development of a multiple-antigen protein fusion vaccine candidate that confers protection against Bacillus anthracis and Yersinia pestis. PLoS Neglected Tropical Diseases, 2019, 13, e0007644. | 1.3 | 10 |
| 27 | Maternal Antibodies Elicited by Immunization With an O- Polysaccharide Glycoconjugate Vaccine Protect Infant Mice Against Lethal Salmonella Typhimurium Infection. Frontiers in Immunology, 2019, 10, 2124. | 2.2 | 2 |
| 28 | mSphere of Influence: the View from the Microbiologists of the Future. MSphere, 2019, 4, . | 1.3 | 0 |
| 29 | A Combined YopB and LcrV Subunit Vaccine Elicits Protective Immunity against Yersinia Infection in Adult and Infant Mice. Journal of Immunology, 2019, 202, 2005-2016. | 0.4 | 4 |
| 30 | Consensus Report on Shigella Controlled Human Infection Model: Immunological Assays. Clinical Infectious Diseases, 2019, 69, S596-S601. | 2.9 | 22 |
| 31 | A Phase 1 dose escalating study of double mutant heat-labile toxin LTR192G/L211A (dmLT) from Enterotoxigenic Escherichia coli (ETEC) by sublingual or oral immunization. Vaccine, 2019, 37, 602-611. | 1.7 | 24 |
| 32 | Completion of an Experiment. MSphere, 2018, 3, . | 1.3 | 0 |
| 33 | Improving Our Understanding of <i>Salmonella enterica</i> Serovar Paratyphi B through the Engineering and Testing of a Live Attenuated Vaccine Strain. MSphere, 2018, 3, . | 1.3 | 7 |
| 34 | Immunogenicity and efficacy following sequential parenterally-administered doses of Salmonella Enteritidis COPS:FliC glycoconjugates in infant and adult mice. PLoS Neglected Tropical Diseases, 2018, 12, e0006522. | 1.3 | 15 |
| 35 | Improved Tolerability of a Salmonella enterica Serovar Typhimurium Live-Attenuated Vaccine Strain Achieved by Balancing Inflammatory Potential with Immunogenicity. Infection and Immunity, 2018, 86, . | 1.0 | 9 |
| 36 | Development of a broad spectrum glycoconjugate vaccine to prevent wound and disseminated infections with Klebsiella pneumoniae and Pseudomonas aeruginosa. PLoS ONE, 2018, 13, e0203143. | 1.1 | 67 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Establishment of the first International Standard for human anti-typhoid capsular Vi polysaccharide IgG. <i>Biologicals</i> , 2018, 56, 29-38. | 0.5 | 20 |
| 38 | A Novel <i>Shigella</i> Proteome Microarray Discriminates Targets of Human Antibody Reactivity following Oral Vaccination and Experimental Challenge. <i>MSphere</i> , 2018, 3, . | 1.3 | 27 |
| 39 | Safety and immunogenicity of a pentavalent meningococcal conjugate vaccine containing serogroups A, C, Y, W, and X in healthy adults: a phase 1, single-centre, double-blind, randomised, controlled study. <i>Lancet Infectious Diseases</i> , The, 2018, 18, 1088-1096. | 4.6 | 63 |
| 40 | Development, Interlaboratory Evaluations, and Application of a Simple, High-Throughput <i>Shigella</i> Serum Bactericidal Assay. <i>MSphere</i> , 2018, 3, . | 1.3 | 31 |
| 41 | Safety and immunogenicity of an oral tablet norovirus vaccine, a phase I randomized, placebo-controlled trial. <i>JCI Insight</i> , 2018, 3, . | 2.3 | 89 |
| 42 | Cytokines Are Markers of the Clostridium difficile-Induced Inflammatory Response and Predict Disease Severity. <i>Vaccine Journal</i> , 2017, 24, . | 3.2 | 90 |
| 43 | Human immune responses against Shigella and enterotoxigenic E. coli : Current advances and the path forward. <i>Vaccine</i> , 2017, 35, 6803-6806. | 1.7 | 22 |
| 44 | A primary human macrophage-enteroid co-culture model to investigate mucosal gut physiology and host-pathogen interactions. <i>Scientific Reports</i> , 2017, 7, 45270. | 1.6 | 274 |
| 45 | Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study. <i>Vaccine Journal</i> , 2017, 24, . | 3.2 | 69 |
| 46 | A Primary Human Macrophage-Enteroid Co-Culture Model to Investigate Mucosal Gut Physiology and Host-Pathogen Interactions. <i>Gastroenterology</i> , 2017, 152, S56-S57. | 0.6 | 1 |
| 47 | Tularemia vaccine: Safety, reactogenicity, â€œTakeâ€skin reactions, and antibody responses following vaccination with a new lot of the Francisella tularensis live vaccine strain â€œ A phase 2 randomized clinical Trial. <i>Vaccine</i> , 2017, 35, 4730-4737. | 1.7 | 30 |
| 48 | Enterotoxigenic Escherichia coli is phagocytosed by macrophages underlying villus-like intestinal epithelial cells: modeling ex vivo innate immune defenses of the human gut. <i>Gut Microbes</i> , 2017, , 00-00. | 4.3 | 16 |
| 49 | Bioactive Immune Components of Anti-Diarrheagenic Enterotoxigenic Escherichia coli Hyperimmune Bovine Colostrum Products. <i>Vaccine Journal</i> , 2017, 24, . | 3.2 | 21 |
| 50 | The Legacy of CVI. <i>Vaccine Journal</i> , 2017, 24, . | 3.2 | 0 |
| 51 | Randomized, Placebo-Controlled, Double-Blind Phase 2 Trial Comparing the Reactogenicity and Immunogenicity of a Single Standard Dose to Those of a High Dose of CVD 103-HgR Live Attenuated Oral Cholera Vaccine, with Shanchol Inactivated Oral Vaccine as an Open-Label Immunologic Comparator. <i>Vaccine Journal</i> , 2017, 24, . | 3.2 | 8 |
| 52 | Immunization Coverage Surveys and Linked Biomarker Serosurveys in Three Regions in Ethiopia. <i>PLoS ONE</i> , 2016, 11, e0149970. | 1.1 | 21 |
| 53 | Springtime for CVI. <i>Vaccine Journal</i> , 2016, 23, 247-247. | 3.2 | 1 |
| 54 | Serological Monitoring Is Key To Sustain Progress of the Maternal and Neonatal Tetanus Elimination Initiative. <i>Vaccine Journal</i> , 2016, 23, 532-534. | 3.2 | 5 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 55 | Characterization of a multicomponent live, attenuated <i>Shigella flexneri</i> vaccine. <i>Pathogens and Disease</i> , 2016, 74, ftw034. | 0.8 | 15 |
| 56 | Opsonophagocytic Assay To Evaluate Immunogenicity of Nontyphoidal Salmonella Vaccines. <i>Vaccine Journal</i> , 2016, 23, 520-523. | 3.2 | 11 |
| 57 | Safety and Immunogenicity of a Parenterally Administered, Structure-Based Rationally Modified Recombinant Staphylococcal Enterotoxin B Protein Vaccine, STEBVax. <i>Vaccine Journal</i> , 2016, 23, 918-925. | 3.2 | 38 |
| 58 | Live Attenuated Human <i>Salmonella</i> Vaccine Candidates: Tracking the Pathogen in Natural Infection and Stimulation of Host Immunity. <i>EcoSal Plus</i> , 2016, 7, . | 2.1 | 35 |
| 59 | <i>Salmonella enterica</i> serovar Typhi and gallbladder cancer: a case-control study and meta-analysis. <i>Cancer Medicine</i> , 2016, 5, 3310-3235. | 1.3 | 102 |
| 60 | Maternal immunisation with trivalent inactivated influenza vaccine for prevention of influenza in infants in Mali: a prospective, active-controlled, observer-blind, randomised phase 4 trial. <i>Lancet Infectious Diseases</i> , The, 2016, 16, 1026-1035. | 4.6 | 196 |
| 61 | Simple method for purification of enterotoxigenic <i>Escherichia coli</i> fimbriae. <i>Protein Expression and Purification</i> , 2016, 119, 130-135. | 0.6 | 4 |
| 62 | Single-dose Live Oral Cholera Vaccine CVD 103-HgR Protects Against Human Experimental Infection With <i>Vibrio cholerae</i> O1 El Tor. <i>Clinical Infectious Diseases</i> , 2016, 62, 1329-1335. | 2.9 | 154 |
| 63 | Functional Activity of Antibodies Directed towards Flagellin Proteins of Non-Typhoidal Salmonella. <i>PLoS ONE</i> , 2016, 11, e0151875. | 1.1 | 19 |
| 64 | Strategies for Coordination of a Serosurvey in Parallel with an Immunization Coverage Survey. <i>American Journal of Tropical Medicine and Hygiene</i> , 2015, 93, 416-424. | 0.6 | 11 |
| 65 | Safety and Immunogenicity of a Vi Polysaccharide-Tetanus Toxoid Conjugate Vaccine (Typbar-TCV) in Healthy Infants, Children, and Adults in Typhoid Endemic Areas: A Multicenter, 2-Cohort, Open-Label, Double-Blind, Randomized Controlled Phase 3 Study. <i>Clinical Infectious Diseases</i> , 2015, 61, 393-402. | 2.9 | 164 |
| 66 | <i>Shigella</i> IpaB and IpaD displayed on <i>L. lactis</i> bacterium-like particles induce protective immunity in adult and infant mice. <i>Immunology and Cell Biology</i> , 2015, 93, 641-652. | 1.0 | 43 |
| 67 | Refined Live Attenuated <i>Salmonella enterica</i> Serovar Typhimurium and Enteritidis Vaccines Mediate Homologous and Heterologous Serogroup Protection in Mice. <i>Infection and Immunity</i> , 2015, 83, 4504-4512. | 1.0 | 10 |
| 68 | A Bivalent Typhoid Live Vector Vaccine Expressing both Chromosome- and Plasmid-Encoded <i>Yersinia pestis</i> Antigens Fully Protects against Murine Lethal Pulmonary Plague Infection. <i>Infection and Immunity</i> , 2015, 83, 161-172. | 1.0 | 21 |
| 69 | Vedolizumab affects antibody responses to immunisation selectively in the gastrointestinal tract: randomised controlled trial results. <i>Gut</i> , 2015, 64, 77-83. | 6.1 | 145 |
| 70 | Safety and Immunogenicity of Single-Dose Live Oral Cholera Vaccine Strain CVD 103-HgR, Prepared from New Master and Working Cell Banks. <i>Vaccine Journal</i> , 2014, 21, 66-73. | 3.2 | 43 |
| 71 | <i>Helicobacter pylori</i> Infection Affects Immune Responses Following Vaccination of Typhoid-Naive US Adults With Attenuated <i>Salmonella</i> Typhi Oral Vaccine CVD 908-htrA. <i>Journal of Infectious Diseases</i> , 2014, 209, 1452-1458. | 1.9 | 18 |
| 72 | Live Oral <i>Salmonella enterica</i> Serovar Typhi Vaccines Ty21a and CVD 909 Induce Opsonophagocytic Functional Antibodies in Humans That Cross-React with <i>S</i> . Paratyphi A and <i>S</i> . Paratyphi B. <i>Vaccine Journal</i> , 2014, 21, 427-434. | 3.2 | 52 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Gut-Homing Conventional Plasmablasts and CD27 ⁺ CD138 ⁺ Plasmablasts Elicited after a Short Time of Exposure to an Oral Live-Attenuated Shigella Vaccine Candidate in Humans. <i>Frontiers in Immunology</i> , 2014, 5, 374. | 2.2 | 21 |
| 74 | Serum Bactericidal Assays To Evaluate Typhoidal and Nontyphoidal Salmonella Vaccines. <i>Vaccine Journal</i> , 2014, 21, 712-721. | 3.2 | 62 |
| 75 | A scalable method for biochemical purification of Salmonella flagellin. <i>Protein Expression and Purification</i> , 2014, 102, 1-7. | 0.6 | 31 |
| 76 | Intradermal Delivery of <i>Shigella</i> IpaB and IpaD Type III Secretion Proteins: Kinetics of Cell Recruitment and Antigen Uptake, Mucosal and Systemic Immunity, and Protection across Serotypes. <i>Journal of Immunology</i> , 2014, 192, 1630-1640. | 0.4 | 52 |
| 77 | Age-Dependent Association among Helicobacter pylori Infection, Serum Pepsinogen Levels and Immune Response of Children to Live Oral Cholera Vaccine CVD 103-HgR. <i>PLoS ONE</i> , 2014, 9, e83999. | 1.1 | 14 |
| 78 | Characterization of systemic and pneumonic murine models of plague infection using a conditionally virulent strain. <i>Comparative Immunology, Microbiology and Infectious Diseases</i> , 2013, 36, 113-128. | 0.7 | 5 |
| 79 | Safety and tolerability of a live oral Salmonella typhimurium vaccine candidate in SIV-infected nonhuman primates. <i>Vaccine</i> , 2013, 31, 5879-5888. | 1.7 | 19 |
| 80 | Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. <i>Vaccine</i> , 2013, 31, 2919-2929. | 1.7 | 44 |
| 81 | Progress and pitfalls in Shigella vaccine research. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2013, 10, 245-255. | 8.2 | 117 |
| 82 | Safety and Immunogenicity of a Single Oral Dose of Recombinant Double Mutant Heat-Labile Toxin Derived from Enterotoxigenic Escherichia coli. <i>Vaccine Journal</i> , 2013, 20, 1764-1770. | 3.2 | 54 |
| 83 | Gut Immunology and Oral Vaccination. , 2013, , 59-84. | | 3 |
| 84 | Sustained Protection in Mice Immunized with Fractional Doses of Salmonella Enteritidis Core and O Polysaccharide-Flagellin Glycoconjugates. <i>PLoS ONE</i> , 2013, 8, e64680. | 1.1 | 49 |
| 85 | Broadly Protective Shigella Vaccine Based on Type III Secretion Apparatus Proteins. <i>Infection and Immunity</i> , 2012, 80, 1222-1231. | 1.0 | 124 |
| 86 | Salmonella enterica Serovar Enteritidis Core O Polysaccharide Conjugated to H:gm Flagellin as a Candidate Vaccine for Protection against Invasive Infection with <i>S. Enteritidis</i> . <i>Infection and Immunity</i> , 2011, 79, 4240-4249. | 1.0 | 114 |
| 87 | Immunology of gut mucosal vaccines. <i>Immunological Reviews</i> , 2011, 239, 125-148. | 2.8 | 207 |
| 88 | Oral priming with Salmonella Typhi vaccine strain CVD 909 followed by parenteral boost with the S. Typhi Vi capsular polysaccharide vaccine induces CD27 ⁺ IgD ⁺ S. Typhi-specific IgA and IgG B memory cells in humans. <i>Clinical Immunology</i> , 2011, 138, 187-200. | 1.4 | 56 |
| 89 | Mucosal IgA Responses in Healthy Adult Volunteers following Intranasal Spray Delivery of a Live Attenuated Measles Vaccine. <i>Vaccine Journal</i> , 2011, 18, 355-361. | 3.2 | 26 |
| 90 | Engineering and Preclinical Evaluation of Attenuated Nontyphoidal Salmonella Strains Serving as Live Oral Vaccines and as Reagent Strains. <i>Infection and Immunity</i> , 2011, 79, 4175-4185. | 1.0 | 89 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 91 | Cell-Associated Flagella Enhance the Protection Conferred by Mucosally-Administered Attenuated Salmonella Paratyphi A Vaccines. <i>PLoS Neglected Tropical Diseases</i> , 2011, 5, e1373. | 1.3 | 48 |
| 92 | Adjuvanted Intranasal Norwalk Virus-Like Particle Vaccine Elicits Antibodies and Antibody-Secreting Cells That Express Homing Receptors for Mucosal and Peripheral Lymphoid Tissues. <i>Journal of Infectious Diseases</i> , 2010, 202, 1649-1658. | 1.9 | 200 |
| 93 | A New Generation of Stable, Nonantibiotic, Low-Copy-Number Plasmids Improves Immune Responses to Foreign Antigens in <i>Salmonella enterica</i> Serovar Typhi Live Vectors. <i>Infection and Immunity</i> , 2010, 78, 337-347. | 1.0 | 38 |
| 94 | Measles DNA vaccine priming for young infants. <i>Procedia in Vaccinology</i> , 2010, 2, 151-158. | 0.4 | 1 |
| 95 | Mucosally Delivered Salmonella Typhi Expressing the Yersinia pestis F1 Antigen Elicits Mucosal and Systemic Immunity Early in Life and Primes the Neonatal Immune System for a Vigorous Anamnestic Response to Parenteral F1 Boost. <i>Journal of Immunology</i> , 2009, 182, 1211-1222. | 0.4 | 24 |
| 96 | Mucosal Immunization with Attenuated <i>Salmonella enterica</i> Serovar Typhi Expressing Protective Antigen of Anthrax Toxin (PA83) Primes Monkeys for Accelerated Serum Antibody Responses to Parenteral PA83 Vaccine. <i>Journal of Infectious Diseases</i> , 2009, 199, 326-335. | 1.9 | 38 |
| 97 | Sindbis Virus-Based Measles DNA Vaccines Protect Cotton Rats against Respiratory Measles: Relevance of Antibodies, Mucosal and Systemic Antibody-Secreting Cells, Memory B Cells, and Th1-Type Cytokines as Correlates of Immunity. <i>Journal of Virology</i> , 2009, 83, 2789-2794. | 1.5 | 22 |
| 98 | <i>Salmonella enterica</i> serovar Typhi live vector vaccines finally come of age. <i>Immunology and Cell Biology</i> , 2009, 87, 400-412. | 1.0 | 77 |
| 99 | An improved Francisella tularensis live vaccine strain (LVS) is well tolerated and highly immunogenic when administered to rabbits in escalating doses using various immunization routes. <i>Vaccine</i> , 2008, 26, 1773-1785. | 1.7 | 48 |
| 100 | Preclinical Safety and Biodistribution of Sindbis Virus Measles DNA Vaccines Administered as a Single Dose or Followed by Live Attenuated Measles Vaccine in a Heterologous Prime-Boost Regimen. <i>Human Gene Therapy</i> , 2008, 19, 522-531. | 1.4 | 10 |
| 101 | Safety and Immunogenicity of CVD 1208S, a Live, Oral <i>Shigella flexneri</i> 2a Vaccine Grown on Animal-Free Media. <i>Hum Vaccin</i> , 2007, 3, 268-275. | 2.4 | 72 |
| 102 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road. <i>Nature Reviews Microbiology</i> , 2007, 5, 540-553. | 13.6 | 303 |
| 103 | Measurement of Tetanus Antitoxin in Oral Fluid. <i>Pediatric Infectious Disease Journal</i> , 2006, 25, 819-825. | 1.1 | 27 |
| 104 | Neonatal Immunization with a Sindbis Virus-DNA Measles Vaccine Induces Adult-Like Neutralizing Antibodies and Cell-Mediated Immunity in the Presence of Maternal Antibodies. <i>Journal of Immunology</i> , 2006, 176, 5671-5681. | 0.4 | 44 |
| 105 | Characterization of Immune Responses Induced by Intramuscular Vaccination with DNA Vaccines Encoding Measles Virus Hemagglutinin and/or Fusion Proteins. <i>Journal of Virology</i> , 2005, 79, 9854-9861. | 1.5 | 29 |
| 106 | A SEROSURVEY TO IDENTIFY THE WINDOW OF VULNERABILITY TO WILD-TYPE MEASLES AMONG INFANTS IN RURAL MALI. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 26-31. | 0.6 | 38 |
| 107 | A serosurvey to identify the window of vulnerability to wild-type measles among infants in rural Mali. <i>American Journal of Tropical Medicine and Hygiene</i> , 2005, 73, 26-31. | 0.6 | 15 |
| 108 | Deletion in the Shigella Enterotoxin Genes Further Attenuates Shigella flexneri 2a Bearing Guanine Auxotrophy in a Phase 1 Trial of CVD 1204 and CVD 1208. <i>Journal of Infectious Diseases</i> , 2004, 190, 1745-1754. | 1.9 | 86 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | Immune Responses to an Oral Typhoid Vaccine Strain That Is Modified to Constitutively Express Vi Capsular Polysaccharide. <i>Journal of Infectious Diseases</i> , 2004, 190, 565-570. | 1.9 | 68 |
| 110 | Adaptation of the Endogenous <i>Salmonella enterica</i> Serovar Typhi <i>clyA</i> -Encoded Hemolysin for Antigen Export Enhances the Immunogenicity of Anthrax Protective Antigen Domain 4 Expressed by the Attenuated Live-Vector Vaccine Strain CVD 908- <i>htrA</i> . <i>Infection and Immunity</i> , 2004, 72, 7096-7106. | 1.0 | 67 |
| 111 | Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. <i>Vaccine</i> , 2004, 22, 4385-4389. | 1.7 | 163 |
| 112 | Animal models paving the way for clinical trials of attenuated <i>Salmonella enterica</i> serovar Typhi live oral vaccines and live vectors. <i>Vaccine</i> , 2003, 21, 401-418. | 1.7 | 91 |
| 113 | Attenuated <i>Salmonella enterica</i> Serovar Typhi and <i>Shigella flexneri</i> 2a Strains Mucosally Deliver DNA Vaccines Encoding Measles Virus Hemagglutinin, Inducing Specific Immune Responses and Protection in Cotton Rats. <i>Journal of Virology</i> , 2003, 77, 5209-5217. | 1.5 | 72 |
| 114 | Concomitant Induction of CD4+ and CD8+ T Cell Responses in Volunteers Immunized with <i>Salmonella enterica</i> Serovar Typhi Strain CVD 908- <i>htrA</i> . <i>Journal of Immunology</i> , 2003, 170, 2734-2741. | 0.4 | 94 |
| 115 | Characterization of CD8+ Effector T Cell Responses in Volunteers Immunized with <i>Salmonella enterica</i> Serovar Typhi Strain Ty21a Typhoid Vaccine. <i>Journal of Immunology</i> , 2002, 169, 2196-2203. | 0.4 | 139 |
| 116 | <i>Salmonella enterica</i> Serovar Typhi Live Vector Vaccines Delivered Intranasally Elicit Regional and Systemic Specific CD8+ Major Histocompatibility Class I-Restricted Cytotoxic T Lymphocytes. <i>Infection and Immunity</i> , 2002, 70, 4009-4018. | 1.0 | 24 |
| 117 | Construction, Genotypic and Phenotypic Characterization, and Immunogenicity of Attenuated Δ guaBA <i>Salmonella enterica</i> Serovar Typhi Strain CVD 915. <i>Infection and Immunity</i> , 2001, 69, 4734-4741. | 1.0 | 49 |
| 118 | In Vivo Characterization of the Murine Intranasal Model for Assessing the Immunogenicity of Attenuated <i>Salmonella enterica</i> Serovar Typhi Strains as Live Mucosal Vaccines and as Live Vectors. <i>Infection and Immunity</i> , 2000, 68, 205-213. | 1.0 | 79 |
| 119 | A comparison of immunogenicity and in vivo distribution of <i>Salmonella enterica</i> serovar Typhi and Typhimurium live vector vaccines delivered by mucosal routes in the murine model. <i>Vaccine</i> , 2000, 18, 3208-3213. | 1.7 | 39 |
| 120 | Attenuated Δ guaBA <i>Salmonella typhi</i> Vaccine Strain CVD 915 as a Live Vector Utilizing Prokaryotic or Eukaryotic Expression Systems to Deliver Foreign Antigens and Elicit Immune Responses. <i>Clinical Immunology</i> , 1999, 92, 76-89. | 1.4 | 67 |
| 121 | Live Attenuated Vectors: Have they Delivered?. , 0, , 72-86. | | 0 |